Selley M L, Glass J, Triggs E J, Thomas J
Clin Pharmacol Ther. 1975 May;17(5):599-605. doi: 10.1002/cpt1975175599.
The pharmacokinetics of the new anti-inflammatory agent tolmetin have been studied after its oral administration to normal subjects and to patients with rheumatoid arthritis. Plasma concentration-time data were fitted to a one-compartment open model. Following single oral doses, no basic differences in rates of drug absorption and elimination were found between normal subjects and arthritic patients. For the 12 subjects studied, the overall mean elimination rate constant was 0.839 hr-1, corresponding to a plasma half-life of 0.83 hr. The drug was rapidly absorbed and had a mean apparent volume of distribution of 0.098 l/kg. Plasma levels and pharmacokinetic parameters of tolmetin in arthritic patients after multiple dosing were smaller to those after a single dose.
新型抗炎药托美丁在正常受试者和类风湿性关节炎患者口服给药后的药代动力学已得到研究。血浆浓度-时间数据符合单室开放模型。单次口服给药后,正常受试者和关节炎患者在药物吸收和消除速率方面未发现基本差异。对于所研究的12名受试者,总体平均消除速率常数为0.839小时⁻¹,对应血浆半衰期为0.83小时。该药物吸收迅速,平均表观分布容积为0.098升/千克。关节炎患者多次给药后托美丁的血浆水平和药代动力学参数比单次给药后要小。